Browsing by Author "Mohamed, R"
Now showing 1 - 7 of 7
Results Per Page
Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from a Malaysian Hospital(Univ Sains Malaysia, Sch Medical Sciences, 2009) ;Pathmanathan, SG ;Samat, NAMohamed, ROngoing surveillance of Pseudomonas aeruginosa resistance against antimicrobial agents is fundamental to monitor trends in susceptibility patterns and to appropriately guide clinicians in choosing empirical or directed therapy. The in vitro activity level of eight antimicrobial drugs was assessed against 97 clinical isolates of P. aeruginosa collected consecutively for three months in 2007 from a Malaysian hospital. Antimicrobial susceptibility was determined using the E-test method in addition to the hospital's routine diagnostic testing by the disk diffusion method. Respiratory and wound swab isolates were the most frequently encountered isolates. The E-test and disk diffusion methods showed high concordance in determining the in vitro activity of the antimicrobial agents against the E isolates. Piperacillin-tazobactam was the most active antimicrobial agent with 91.8% susceptibility, followed by the aminoglycosides (amikacin, 86.6% and gentamicin, 84.5%), the quinolone (ciprofloxacin, 83.5%) and the beta-lactams (cefepime, 80.4%, ceftazidime, 80.4%, imipenem, 79.4% and meropenem, 77.3%). Incidence of multidrug resistance was 19.6% (19 out of 97 isolates). Periodic antibiotic resistance surveillance is fundamental to monitor changes in susceptibility patterns in a hospital setting. - Some of the metrics are blocked by yourconsent settings
Publication Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia(Springer India, 2016) ;Prof. Madya Dr. Asral Wirda Binti Ahmad Asnawi ;Sathar, J ;Mohamed, R ;Deraman, R ;Kumaran, S ;Abd Hamid, SSZakaria, MZClinical manifestations of sickle cell disease (SCD) arise from the tendency of the sickle haemoglobin to polymerize and deform red blood cells into the characteristic sickle shape. Sickle cell crisis is a devastating complication that may occur in patients with SCD. If not managed properly permanent organ damage and even death may be the final outcome. A case of a 32-year-old Nigerian lady, Gravida 1 Para 0 in her first trimester, with SCD who developed signs and symptoms of delayed haemolytic transfusion reaction after receiving packed red cell transfusion is demonstrated. Multiple red cell alloantibodies were detected in the patient's plasma; anti-Fy a, anti-Jk b and anti-E. The patient miscarriaged and succumbed to complications of hyperhaemolysis with delayed haemolytic transfusion reaction, acute chest syndrome and renal failure. There is an urgent need for mandatory red cell antibody screen and identification especially in high-risk cases. Prevention of alloimmunization by supplying phenotype-specific red cells is also required. - Some of the metrics are blocked by yourconsent settings
Publication Hepatitis C and kidney disease: An overview and approach to management(Baishideng Publishing Group Inc, 2015) ;Azmi, AN ;Tan, SSMohamed, RHepatitis C infection and chronic kidney disease are major health burden worldwide. Hepatitis C infection is associated with a wide range of extra-hepatic manifestations in various organs including the kidneys. A strong association between hepatitis C and chronic kidney disease has come to light. Hemodialysis in supporting the end stage renal disease patients unfortunately carries a risk for hepatitis C infection. Despite much improvement in the care of this group of patients, the prevalence of hepatitis C infection in hemodialysis patients is still higher than the general population. Hepatitis C infection has a negative effect on the survival of hemodialysis and renal transplant patients. Treatment of hepatitis C in end stage renal disease patients using conventional or pegylated interferon with or without ribavirin remains a clinical challenge with low response rate, high dropout rate due to poor tolerability and many unmet needs. The approval of new direct acting antiviral agents for hepatitis C may dramatically change the treatment approach in hepatitis C infected patients with mild to moderate renal impairment. However it remains to be confirmed if the newer Hepatitis C therapies are safe in individuals with severe renal impairment. This review article discusses the relationship between hepatitis C and chronic kidney disease, describe the various types of renal diseases associated with hepatitis C and the newer as well as the existing treatments for hepatitis C in the context of this subpopulation of hepatitis C patients. - Some of the metrics are blocked by yourconsent settings
Publication Homozygous southeast asian hereditary ovalostomatocytosis: Management dilemma(Wiley-Blackwell, 2015) ;Asnawi, AWA ;Sathar, J ;Nasir, SFSM ;Mohamed, R ;Jayaprakasam, KVVellapandian, ST - Some of the metrics are blocked by yourconsent settings
Publication Out-Of-Pocket And Catastrophic Health Expenditures Among Hepatitis C Patients: Results From A Middle-Income Country(Elsevier Science Inc, 2018) ;Azzeri, A ;Shabaruddin, FH ;Jaafar, H ;Mohamed, RDahlui, M - Some of the metrics are blocked by yourconsent settings
Publication Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates(Baishideng Publishing Group Inc, 2014) ;Azmi, AN ;Tan, SSMohamed, RThe natural history of chronic hepatitis B is characterized by different phases of infection, and patients may evolve from one phase to another or may revert to a previous phase. The hepatitis B e antigen (HBeAg)negative form is the predominant infection worldwide, which consists of individuals with a range of viral replication and liver disease severity. Although alanine transaminase (ALT) remains the most accessible test available to clinicians for monitoring the liver disease status, further evaluations are required for some patients to assess if treatment is warranted. Guidance from practice guidelines together with thorough investigations and classifications of patients ensure recognition of who needs which level of care. This article aims to assist physicians in the assessment of HBeAg-negative individuals using liver biopsy or non-invasive tools such as hepatitis B s antigen quantification and transient elastography in addition to ALT and hepatitis B virus DNA, to identify who will remain stable, who will reactivate or at risk of disease progression hence will benefit from timely initiation of anti-viral therapy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Pseudomonas aeruginosa: Antimicrobial Susceptibility Testing and Agreement Between Disk Diffusion and E-Test Methods(Elsevier Sci Ltd, 2008) ;Pathmanathan, SG ;Samat, NAMohamed, RBackground: The intrinsic resistance of Pseudomonas aeruginosa towards several antimicrobial agents has contributed to its role as an effective opportunistic pathogen and its emergence as one of the most problematic human pathogens. The aim of this study was to assess the susceptibility patterns of eight commonly used antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Methods: A total of 97 Pseudomonas aeruginosa strains were isolated from various clinical specimens at the Kuala Lumpur Hospital, Malaysia between October and December 2007. Antimicrobial susceptibility was determined using the E-test method subsequent to the hospital's routine diagnostic testing by the disk diffusion (DD) method. Results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: Total agreement of DD and E-test methods was 99% for susceptibility to gentamicin, ciprofloxacin and ceftazidime, 98% for susceptibility to amikacin, piperacillin/tazobactam, imipenem and meropenem and 97% for susceptibility to cefepime. According to the E-test method, the rates of susceptible isolates were piperacillin/tazobactam 91%, amikacin 87%, gentamicin 85%, ciprofloxacin 84%, ceftazidime and cefepime 80% each, imipenem 79% and meropenem 77%. 24% of the isolates were resistant to two or more antimicrobial agents.